Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“It was an important Third Quarter at Pfizer, and I’m proud of the focus from the R and D organization to lead impactful science that will translate into potential medicines and vaccines for patients. I wanted to share just a snapshot of what has kept the innovation engine going over the last few months and what’s fueling our work into the future.
Our science had an important presence at ESMO. With 48 abstracts, including five late-breaking presentations and recognition in the Presidential Symposium, the momentum with our Oncology portfolio is strong. Here are a few highlights from Pfizer’s presence at ESMO:
- Pivotal Phase 3 data from our ADC in combination with immunotherapy in people with muscle-invasive Bladder Cancer who are ineligible for or decline cisplatin-based chemotherapy.
- Updated long-term overall survival (OS) results from our Phase 2 single-arm study of a targeted combination therapy in patients with metastatic non-small cell Lung Cancer (NSCLC) with a BRAF V600E mutation.
- In collaboration with Astellas Pharma, we shared final Phase 3 overall survival data in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
- Open-label extension data from our Phase 2 study of our anti-GDF-15 antibody in cancer cachexia, which demonstrated continued improvements in body weight through 64 weeks.
Over the last few months we also initiated several key Phase 3 registration-intent studies with potential first-in-class programs, including an ADC targeting integrin-b6 for lung cancer, an EZH2 inhibitor in combination with an androgen receptor pathway inhibitor for men with metastatic hormone-sensitive prostate cancer (mHSPC or mCSPC), a vaccine candidate for Group B Streptococcus, and a small molecule targeting KAT6 for breast cancer, among others.
Thank you to everyone who plays a critical role in moving our science forward. Congratulations on a job well done and onward to finish 2025 with even more health impact with our science.”
More posts featuring Chris Boshoff.